阿比特龙与恩扎卢胺真实世界住院不良事件比较
基于法国国家健康保险数据库,纳入2013至2017年新使用阿比特龙或恩扎卢胺的前列腺癌患者并随访至2018年底,在无禁忌或注意事项的子人群中用泊松模型估计住院不良事件发生率比。阿比特龙组急性肾损伤、提示肝损害的肝脏监测及房颤发生率显著高于恩扎卢胺组。
要点
- 阿比特龙组急性肾损伤住院风险显著高于恩扎卢胺组(IRR 1.42)。
- 阿比特龙组提示肝损害的肝脏监测事件显著更多(IRR 3.06)。
- 阿比特龙组房颤住院风险轻度但显著增高(IRR 1.12)。
核心结论
- 真实世界中阿比特龙较恩扎卢胺与更高的急性肾损伤、提示肝损害的肝脏监测及房颤住院风险相关。
- 急性肾损伤安全信号与法国药物警戒数据库分析结果一致,需进一步专项研究。
- 研究提示临床医生使用阿比特龙时应保持谨慎。
研究设计与样本
- 基于法国国家健康保险系统数据库的法国人群队列研究。
- 纳入2013至2017年新暴露于阿比特龙或恩扎卢胺的患者,随访至2018年12月31日。
- 在无两种治疗禁忌或使用注意事项的子人群中,用泊松模型估计各事件的发生率比(IRR)。
主要发现
- 共纳入11 534名阿比特龙和恩扎卢胺新使用者。
- 急性肾损伤(AKI)IRR 1.42(95% CI: 1.01-2.00),阿比特龙高于恩扎卢胺。
- 提示肝损害的肝脏监测IRR 3.06(95% CI: 2.66-3.53),阿比特龙高于恩扎卢胺。
- 房颤IRR 1.12(95% CI: 1.05-1.19),阿比特龙高于恩扎卢胺。
临床怎么用
- 使用阿比特龙的前列腺癌患者应加强肾功能、肝功能及房颤相关监测。
- 临床选择阿比特龙或恩扎卢胺时,可结合上述真实世界住院风险信号进行个体化权衡。
局限性
- 研究缺乏临床数据。
- 作者指出研究存在若干局限性,但摘要未逐一列出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Safety profiles of abiraterone and enzalutamide rely mainly on Phase III clinical trials. Our objective was to estimate the incidence rate ratio (IRR) for certain adverse events leading in real life to hospitalization (atrial fibrillation, acute heart failure, ischaemic heart disease, acute kidney injury [AKI], ischaemic stroke, torsade de pointe/QT interval prolongation, hepatitis and seizure), comparing abiraterone to enzalutamide. We also set out to discuss previously identified safety signals. METHOD: Using the French National Health Insurance System database, all patients newly exposed to abiraterone or enzalutamide between 2013 and 2017 and followed until 31 December 2018 were targeted. IRRs for each event were estimated using a Poisson model in a sub-population of patients without contraindications or precautions for use for either treatment. RESULTS: Among 11 534 new users of abiraterone and enzalutamide, AKI (IRR 1.42, 95% CI: 1.01-2.00), liver monitoring suggestive of hepatic damage (IRR 3.06, 95% CI: 2.66-3.53) and atrial fibrillation (IRR 1.12, 95% CI: 1.05-1.19) were significantly more often observed with abiraterone than with enzalutamide. CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalization. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians being cautious in the use of abiraterone.
引用
- Scailteux LM, Despas F, Balusson F, et al. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients. Br J Clin Pharmacol. 2021. PMID: 34224605. doi:10.1111/bcp.14972
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。